


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula (1):

Formula 1



wherein

R¹, R² and R⁵ are each independently selected from a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group which may be substituted with one or more halogen atoms and a C₁-C₆ alkoxy group which may be substituted with one or more halogen atoms;

R³ and R⁴ are each independently selected from a hydrogen atom, a halogen atom, -NRfRg, -CONRfRg, -CH=NORe, a C₁-C₆ alkoxy group, a C₁-C₆ alkyl group and -T-(CH₂)_k-V, wherein the alkyl group and the alkoxy group may be substituted with one or more substituents selected from a hydroxyl group, a C₁-C₆ alkoxy group, a halogen atom and -NRfRg;

wherein

Re is selected from a hydrogen atom and C₁-C₆ alkyl,
wherein the alkyl group may be substituted with one to
three substituents selected from a hydroxyl group, a
C₁-C₆ alkoxy group, a halogen atom and -NRhRi,

Rf and Rg are each independently selected from a
hydrogen atom, C₁-C₆ alkyl group and C₁-C₆
alkylcarbonyl group, wherein the alkyl group and the
alkylcarbonyl group may be substituted with one to
three substituents selected from a hydroxyl group, a
C₁-C₆ alkoxy group, a halogen atom and -NRhRi,

Rh and Ri are each independently selected from a
hydrogen atom and C₁-C₆ alkyl group, wherein the alkyl
group may be substituted with one to three
substituents selected from a hydroxyl group, a halogen
atom and a C₁-C₆ alkoxy group, or

Rf and Rg, and Rh and Ri together with a nitrogen atom
to which they are attached may form a 4- to 7-
heterocycle, wherein the heterocycle may be
substituted with a C₁-C₆ alkyl group,

T is an oxygen atom or a single bond; k is an integer
selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be
substituted with one or more Y³, -NRaRb, -

CONRaRb, -OC(=O)NRaRb, -SO₂NRaRb, -N(-
Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORD, -C(=O)ORD, -
S(=O)_m-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -
N(Ra)SO₂Rc, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -
C(=O)Rc;

R⁶ and R⁷ are each independently selected from a
hydrogen atom and a halogen atom;

Z¹ and Z² are each independently selected from a
hydrogen atom, a hydroxyl group and -O(CHR¹¹)OC(=O)R¹²;


wherein

R¹¹ is a hydrogen atom or a C₁-C₆ alkyl group;

R¹² is a pyrrolidinyl group, a piperidinyl group, a
morpholinyl group, a piperazinyl group, an amino C₁-C₆
alkyl group, a mono- or di(C₁-C₆ alkyl)amino C₁-C₆ alkyl
group, an amino C₁-C₆ alkylamino group or a mono- or
di(C₁-C₆ alkyl)-amino C₁-C₆ alkylamino group;

Q is a group of

Formula 2



wherein

~~G¹ is C-Y² or N₇~~

~~ring A is a benzene ring or a 5 to 6 membered
unsaturated heterocycle; a nitrogen atom present in
the heterocycle may be an N oxide; and the ring A may
be substituted with one to three same or different
substituents W;~~

~~Y¹ and Y² are each~~ is independently selected from a
hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a
C₂-C₆ alkenyl group, a C₁-C₆ alkoxy group, a mono- or
dihydroxy C₁-C₆ alkyl group, a C₁-C₆ alkoxy C₁-C₆ alkoxy
group, an amino C₁-C₆ alkoxy group, a (C₁-C₆ alkyl)amino
C₁-C₆ alkoxy group, a di(C₁-C₆ alkyl)amino C₁-C₆ alkoxy
group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, an amino C₁-C₆
alkyl group, a (C₁-C₆ alkyl)amino C₁-C₆ alkyl group, a
di(C₁-C₆ alkyl)amino C₁-C₆ alkyl group, an amino group,
a (C₁-C₆ alkyl)amino group and a di(C₁-C₆ alkyl)amino
group;

Wherein

Q is optionally substituted by at least one substituents

W, where W is a halogen atom, a nitro group, a cyano
group, a hydroxyl group, -NRaRb, -N=C(-Rc)NRaRb, -
CONRaRb, -OC(=O)NRaRb, -SO₂NRaRb, -N(-
Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -
N[C(=O)ORd][C(=O)ORd'], -C(=O)ORd, -S(=O)_m-
Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -

$N[C(=O)Rc][C(=O)Rc']$, $-N(-Ra)SO_2Rc$, $-N(SO_2Rc)(SO_2Rc')$, $-C(=NORd)NRa'Rb'$, $-C(=NRa)NRa'Rb'$, $-C(=NORa)Rc$, $-C(=O)Rc$, a C_1-C_6 alkyl group which may be substituted with one or more Y^3 , a C_2-C_7 alkenyl group which may be substituted with one or more Y^3 , a C_2-C_7 alkynyl group which may be substituted with one or more Y^3 , an aryl group which may be substituted with one or more Y^3 or a heteroaryl group which may be substituted with one or more Y^3 ;

Ra , Ra' , Rb , Rb' , Rc , Rc' , Rd and Rd' are each independently selected from a hydrogen atom, a C_1-C_{10} alkyl group, a C_3-C_8 cycloalkyl group, a C_2-C_8 alkenyl group, a C_2-C_8 alkynyl group, $-[(C_1-C_6 \text{ alkylene})-O]_n-(C_1-C_3 \text{ alkyl})$, a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a C_1-C_3 alkyl group); or

Ra and Rb , Ra' and Rb' , Ra and Rd , Ra and Ra' , Ra and Rc , Rc and Rc' , and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a C_1-C_6 alkyl group;


~~Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' each may be substituted with one to three same or different substituents selected from Y³;~~
~~m is an integer selected from 0 to 2;~~
~~n is an integer selected from 1 to 4;~~
~~Y³ is a halogen atom, NRxRy, C(=O)ORz, C(=O)Rz, ORz, C(=O)NRxRy, OC(=O)NRxRy, SO₂NRxRy, N(Rx)C(=O)NRx'Ry', N(Rx)C(=O)ORz, S Rz, SO Rz, SO₂ Rz, OC(=O)Rz, N(Rx)C(=O)Rz, C(=NORz)NRx'Ry', C(=NRx)NRx'Ry', C(=NORx)Rz, [O-(C₁-C₆ alkylene)]_n-O(C₁-C₃ alkyl), N(Rx)-(C₁-C₆ alkylene)-O(C₁-C₃ alkyl), C(=O)Rz, a C₁-C₆ alkyl group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, an aryl group or a heteroaryl group;~~
~~Rx, Rx', Ry, Ry' and Rz are each independently selected from a hydrogen atom and a C₁-C₄ alkyl group;~~
~~Rx and Ry, Rx and Rx', Rx and Rz, and Rz and Rx' may form a saturated or unsaturated 5 to 6 membered heterocycle by ring closing at the bonding position of each of these two groups;~~


a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. (Original) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein R^2 is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.

3. (Currently Amended) The compound of claim ~~1~~ 2,
a pharmaceutically acceptable salt thereof or a prodrug
thereof, wherein Q is a group of the formula selected from
Formula 3





which may be substituted with one to three same or different substituents W.

Claims 4-5 (Cancelled)

6. (Previously Presented) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

R^6 and R^7 are hydrogen atoms; and

Z^1 and Z^2 are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Previously Presented) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, a C_1 - C_6 alkyl group which may be substituted with one or more hydroxyl

groups or halogen atoms, a C₁-C₆ alkoxy group which may be substituted with one or more halogen atoms, and -T-(CH₂)_k-V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C₁-C₆ alkyl group, C₁-C₆ alkoxy group and C₁-C₆ alkylcarbonyl group.

8. (Previously Presented) A compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. (Previously Presented) A pharmaceutical composition comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

10. (Previously Presented) An Raf inhibitor or an angiogenesis inhibitor comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

11. (Previously Presented) A preventive or therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

Claims 12-13 (Cancelled)